Percutaneous transcatheter closure of patent foramen ovale in patients with paradoxical embolism

Pollice, Francesco; Pollice, Paolo; Jacob, Lyan

doi:10.15511/ejcm.14.00403

Cited by 2 publications

(2 citation statements)

References 16 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The safety and viability of these devices have been assessed in several studies. [24][25][26][27] These devices have also been safely used in the closure of ASDs in several patients. The device-related complications that might occur are classified as major vascular complications and major adverse device events.…”

Section: Medical Therapy Vs Pfo Closure For Csmentioning

confidence: 99%

Cryptogenic Stroke: To Close a Patent Foramen Ovale or Not to Close?

Kottoor¹,

Arora

2018

J Cent Nerv Syst Dis

View full text Add to dashboard Cite

A patent foramen ovale (PFO) has been shown to be highly prevalent in patients diagnosed with strokes of unknown cause, which are also called cryptogenic strokes (CSs). It has been a long-running controversy as to whether a PFO should be closed or not to prevent recurrent strokes in patients diagnosed with CS. A paradoxical embolism that is produced through a PFO is hypothesized to be a leading cause of CS, especially in younger patients with low risk factors for stroke. It remains controversial as to which anticoagulation therapy, defined as antithrombin or antiplatelet therapy, is better for patients with CS and a PFO. In addition, surgical and transcutaneous closure of a PFO has been proposed for the secondary prevention of stroke in patients with CS with PFO. Several randomized controlled trials have been conducted in recent years to test whether a PFO closure gives a significant benefit in the management of CS. Three earlier randomized controlled trials failed to show a statistically significant benefit for a PFO closure; thus, many investigators believed that a PFO was an incidental bystander in patients with CS. However, meta-analyses and more recent specific trials have eliminated several confounding factors and possible biases and have also emphasized the use of a shunt closure over medical therapy in patients with CS. Therefore, these latest studies (the CLOSE and REDUCE trials) can possibly change the treatment paradigm in the near future.

show abstract

Section: Medical Therapy Vs Pfo Closure For Csmentioning

confidence: 99%

Cryptogenic Stroke: To Close a Patent Foramen Ovale or Not to Close?

Kottoor¹,

Arora

2018

J Cent Nerv Syst Dis

View full text Add to dashboard Cite

show abstract

“…It was initially recommended for the prevention of recurrent strokes in 1992. The safety and viability of these devices have been assessed in several studies [22][23][24][25] . These devices have also been safely used in the closure of ASDs in several patients.…”

mentioning

confidence: 99%

Patent Foramen Ovale Device Closure in a 27 Years Old Young Lady with Cryptogenic Ischaemic Stroke - First Case Report from Bangladesh

Reza¹,

Karim²,

Khan³

et al. 2021

Cardiovasc. j.

View full text Add to dashboard Cite

A patent foramen ovale (PFO) is highly prevalent in patients with strokes of unknown cause or cryptogenic strokes (CSs). It has been remained an unsolved question as to whether a PFO should be closed or not to prevent recurrent strokes in patients diagnosed with cryptogenic stroke (CS). A paradoxical embolism through a PFO is pointed as a leading cause of CS, especially in younger patients with low risk factors for stroke. It also remains an unsolved matter on type of anti-coagulation therapy, which would be better for patients with CS and a PFO. In addition, surgical and transcutaneous closure of a PFO has been proposed for the secondary prevention of stroke in patients with CS with PFO. Several randomized controlled trials have been conducted in recent years to test whether a PFO closure gives a significant benefit in the management of CS. Many investigators believed that a PFO was an incidental finding in patients with CS. However, meta-analyses and more recent specific trials have eliminated several confounding factors and possible biases and have also emphasized the use of a shunt closure over medical therapy in patients with CS. Therefore, these latest studies can possibly change the treatment paradigm in the near future. We are reporting a case of cryptogenic ischaemic stroke in middle cerebral artery territory due to paradoxical embolism through a PFO which was successfully closed with a device solely by a Bangladeshi Consultant & his team first time in Bangladesh. Cardiovasc. j. 2021; 13(2): 227-234

show abstract

Percutaneous transcatheter closure of patent foramen ovale in patients with paradoxical embolism

Cited by 2 publications

References 16 publications

Cryptogenic Stroke: To Close a Patent Foramen Ovale or Not to Close?

Cryptogenic Stroke: To Close a Patent Foramen Ovale or Not to Close?

Patent Foramen Ovale Device Closure in a 27 Years Old Young Lady with Cryptogenic Ischaemic Stroke - First Case Report from Bangladesh

Contact Info

Product

Resources

About